Camp4 Therapeutics Corp
About Camp4 Therapeutics Corp
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.5M
- Net income
- -$80.4M
- Total assets
- $117.8M
- Market cap
- $213.4M
- Operating margin
- -1502.4%
- Net margin
- -2298.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.5M
- Operating expenses
- $56.1M
- Operating income
- -$52.6M
- Income tax
- $0
- Net income
- -$80.4M
- EPS (basic)
- $-2.65
- EPS (diluted)
- $-2.65
Balance sheet
- Total assets
- $117.8M
- Current assets
- $114.1M
- Total liabilities
- $70.1M
- Current liabilities
- $15.5M
- Shareholders’ equity
- $47.7M
Cash flow
- Operating cash flow
- -$29.6M
- Investing cash flow
- -$243.0K
- Financing cash flow
- $75.9M
- Net cash flow
- $46.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $213.4M
- EPS (diluted)
- $-2.65
- Shares outstanding
- 52.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 11, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $80.4M in FY2025.
- Revenue declined 99% from FY2021 to FY2025.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Camp4 Therapeutics Corp.
Write a review
News about Camp4 Therapeutics Corp
News & sentiment via Polygon.io
